Evaluate the effectiveness and safety of traditional Chinese medicine compound in improving radiotherapy-induced oral mucositis in patients with head and neck malignant tumors.
Patients pathologically diagnosed with non-metastatic head and neck malignant tumors;
Age range: 18 to 65 years old (including 18 and 65 years old);
Eastern Cooperative Oncology Group performance status of ≤2;
Radiotherapy or concurrent chemoradiotherapy is required;
Allergic constitution (such as those known to be allergic to two or more drugs);
Patients who plan to use drugs that can cause or worsen oral mucosal inflammation (such as anti EGFR monoclonal antibodies, immune checkpoint inhibitors, etc.) after the start of radiotherapy;
Use of antibiotics, antifungal drugs, or antimicrobial mouthwash within 1 month of the study;
Poor oral hygiene and/or severe periodontal diseases;